Search

BioCryst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

8.23 1.48

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.08

Massimo

8.36

Metriche Chiave

By Trading Economics

Entrata

800M

78M

Vendite

62M

218M

P/E

Media del settore

7.603

56.597

EPS

0.3

Margine di Profitto

35.92

Dipendenti

435

EBITDA

799M

99M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+149.04% upside

Dividendi

By Acuity

Utili prossimi

2 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

306M

2.5B

Apertura precedente

6.75

Chiusura precedente

8.23

Notizie sul Sentiment di mercato

By Acuity

54%

46%

262 / 339 Classifica in Healthcare

BioCryst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 set 2026, 20:08 UTC

Macro Event

BioCryst Pharmaceuticals Inc is lower today, continuing a seven-session decline amid macroeconomic data showing inflation rates in line with expectations.

10 set 2026, 23:26 UTC

No specific news was identified for BioCryst Pharmaceuticals Inc. in after-market trading. Shares remained effectively flat since Thursday's close.

9 set 2026, 23:46 UTC

BioCryst Pharmaceuticals Inc. shares are higher in after-market trading, despite a generally flat performance and remaining below their 20-day moving average.

8 set 2026, 23:16 UTC

BioCryst Pharmaceuticals shares are higher in after-market hours, despite four consecutive lower closes. No specific news was identified to explain the price movement.

3 set 2026, 20:07 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday. No specific news has been identified to explain the movement.

2 set 2026, 23:46 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours. No specific news was identified to explain the decline amid broader market sentiment shifts.

1 set 2026, 22:26 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market hours following a stable performance. No specific news was identified to explain the price movement.

31 ago 2026, 20:07 UTC

BioCryst Pharmaceuticals Inc shares are lower today amid broader market declines following inflation concerns from the Jackson Hole Economic Symposium.

28 ago 2026, 19:16 UTC

News

BioCryst Pharmaceuticals shares are lower despite reporting Q2 2026 revenue of $218.3 million, reflecting broader market trends and valuation discounts.

27 ago 2026, 20:07 UTC

BioCryst Pharmaceuticals shares are higher as positive jobless claims data boosts market sentiment. The stock stabilized after reaching a session high.

26 ago 2026, 19:36 UTC

Event

BioCryst Pharmaceuticals received marketing approval for ORLADEYO in pediatric patients. Shares are lower today amid broader market trends and inflation data.

24 ago 2026, 19:26 UTC

BioCryst Pharmaceuticals Inc shares are trading higher, maintaining a position above the 20-day moving average and near the midpoint of their one-month range.

21 ago 2026, 22:26 UTC

BioCryst Pharmaceuticals shares moved higher in after-hours trading, reaching a session high before slightly retracing. No specific news was identified to explain the movement.

20 ago 2026, 20:01 UTC

Correlated Moves
Social Media

BioCryst Pharmaceuticals Inc shares are lower amid a decline in the Biotechnology sub-sector. Earlier in the session, shares rebounded from a session high.

19 ago 2026, 23:01 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, retracing from an earlier uptick with no specific news identified to explain the decline.

18 ago 2026, 20:06 UTC

BioCryst Pharmaceuticals Inc shares are declining amid broader market weakness, with no specific news identified to explain today's price movement.

14 ago 2026, 19:06 UTC

BioCryst Pharmaceuticals is lower today, following broader market concerns over an unexpected drop in U.S. retail sales impacting Federal Reserve interest rate policy.

13 ago 2026, 21:31 UTC

BioCryst Pharmaceuticals shares traded roughly flat in after-market hours, remaining within their one-month range and above the 20-day moving average.

12 ago 2026, 19:41 UTC

BioCryst Pharmaceuticals shares are higher today, rebounding from an earlier dip and reflecting notable volatility during the session. The stock remains above its 20-day moving average.

11 ago 2026, 23:26 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market weakness and cautious sentiment.

10 ago 2026, 19:51 UTC

News

BioCryst Pharmaceuticals Inc. shares are higher after Wall Street Zen upgraded its rating to "strong-buy." Other firms also adjusted price targets amid market uncertainty.

7 ago 2026, 19:56 UTC

BioCryst Pharmaceuticals is trading higher, continuing a positive trend amid easing concerns over interest rate hikes following a disappointing jobs report.

6 ago 2026, 22:36 UTC

BioCryst Pharmaceuticals shares are lower in after-market trading, continuing a decline since Thursday's close and positioned below the 20-day moving average.

5 ago 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, despite no specific news identified to explain the movement. They remain below their 20-day moving average.

4 ago 2026, 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3 ago 2026, 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31 lug 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30 lug 2026, 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29 lug 2026, 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28 lug 2026, 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

Confronto tra pari

Modifica del prezzo

BioCryst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

149.04% in crescita

Previsioni per 12 mesi

Media 20.222 USD  149.04%

Alto 32 USD

Basso 11 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per BioCryst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

7

Acquista

2

Mantieni

0

Vendi

Sentiment

By Acuity

262 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat